The Library
A first-in-human study of the novel HIV-fusion inhibitor C34-PEG-Chol
Tools
Tools
Tools
Quinn, Killian, Traboni, Cinzia, Penchala, Sujan Dily, Bouliotis, Georgios, Doyle, Nicki, Libri, Vincenzo, Khoo, Saye, Ashby, Deborah, Weber, Jonathan, Nicosia, Alfredo, Cortese, Riccardo, Pessi, Antonello and Winston, Alan (2017) A first-in-human study of the novel HIV-fusion inhibitor C34-PEG-Chol. Scientific Reports, 7 (1). 9447. doi:10.1038/s41598-017-09230-0
|
PDF
WRAP-first-in-human-study-novel-HIV-fusion-inhibitor-C34-PEG-Chol-Bouliotis-2019.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1164Kb) | Preview |
Official URL: https://doi.org/10.1038/s41598-017-09230-0
Abstract
Long-acting injectable antiretroviral (LA-ARV) drugs with low toxicity profiles and propensity for drug-drug interactions are a goal for future ARV regimens. C34-PEG-Chol is a novel cholesterol tagged LA HIV-fusion-inhibitor (FI). We assessed pre-clinical toxicology and first-in-human administration of C34-PEG-Chol. Pre-clinical toxicology was conducted in 2 species. HIV-positive men were randomised to a single subcutaneous dose of C34-PEG-Chol at incrementing doses or placebo. Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacokinetic (time-to-minimum-effective-concentration (MEC, 25 ng/mL) and pharmacodynamic (plasma HIV RNA) parameters were assessed. In both mice and dogs, no-observed-adverse effect level (NOAEL) was observed at a 12 mg/kg/dose after two weeks. Of 5 men enrolled, 3 received active drug (10 mg, 10 mg and 20 mg). In 2 individuals grade 3 ISR occurred and the study was halted. Both ISR emerged within 12 hours of active drug dosing. No systemic toxicities were observed. The time-to-MEC was >72 and >96 hours after 10 and 20 mg dose, respectively, and mean change in HIV RNA was -0.9 log10 copies/mL. These human pharmacodynamic and pharmacokinetic data, although limited to 3 subjects, of C34-PEG-4-Chol suggest continuing evaluation of this agent as a LA-ARV. However, alternative administration routes must be explored.
| Item Type: | Journal Article | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine |
|||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
|||||||||
| Library of Congress Subject Headings (LCSH): | HIV infections -- Chemotherapy, Antiretroviral agents | |||||||||
| Journal or Publication Title: | Scientific Reports | |||||||||
| Publisher: | Nature Publishing Group | |||||||||
| ISSN: | 2045-2322 | |||||||||
| Official Date: | 25 August 2017 | |||||||||
| Dates: |
|
|||||||||
| Volume: | 7 | |||||||||
| Number: | 1 | |||||||||
| Article Number: | 9447 | |||||||||
| DOI: | 10.1038/s41598-017-09230-0 | |||||||||
| Status: | Peer Reviewed | |||||||||
| Publication Status: | Published | |||||||||
| Access rights to Published version: | Open Access | |||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
